Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.08.009
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PCN169 Differences in the Use of Innovative Anti-Cancer Drugs Among French Hospitals

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Prm34 - French Efficiency Opinions of the Economic and Public Health Committee (Ceesp): Is There an Impact on the Market Access for Innovative Drugs?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Prm112 - Incorporation of Anti-Cancer Drugs Adverse Events in Health Economic Opinions of the French National Authority for Health (Has)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Critical Evaluation of the Efficacy of New Drugs

Postgraduate Medical Journal
Medicine
1957English

Pcn355 - Utility in French Health-Economic Opinions: Key Learnings of a Retrospective Analysis in Oncology Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Potential Effects of Introducing Behind the Counter Drugs

2008English

Evaluation of Conflict of Interest in Economic Analyses of New Drugs Used in Oncology

JAMA - Journal of the American Medical Association
Medicine
1999English

Pss9 - Drugs Utilisation in the Italian Setting: The Case of Wamd, Dme and Rvo

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Ethics Codes and Use of New and Innovative Drugs

British Journal of Clinical Pharmacology
Pharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy